Resveratrol has a potential protective effect on several major eye disorders such as age-related macular degeneration, glaucoma, cataracts, and diabetic retinopathy through several pathways, namely anti-inflammatory, antioxidant, anti-apoptotic and anti-angiogenesis In this study, an in vivo study was carried out on experimental animals of Rattus Norvegicus which were given an intervention by injection of intravitreal Resveratrol after ischemia-reperfusion injury to assess the expression of Tumor Necrosis Factor-α (TNF-α) and the number of retinal ganglion cells stained with Brn3a. Ischemia-reperfusion (I/R) injury was done through cannulation in the anterior chamber and pressure was maintained at 110 mmHg for 60 minutes. Resveratrol (RSV) 100M was injected intravitreally in the RSV+IR7 group. After 7 days, the rat’s eye was enucleated. Immunohistochemistry of TNF-α expression in the retina and the number of RGC stained with Brn3a were evaluated. Intravitreal injection of Resveratrol at 100 µM effectively reduced the TNF-α expression compared to the PBS+IR7 group (P< 0.05) suggesting the anti-inflammatory effect of RSV intravitreal after ischemia-reperfusion injury. Intravitreal injection of Resveratrol enhance the survival of retinal ganglion cells (2.66 ± 0.73) in 7 days compared to the PBS+IR7 group (p<0.001). This study showed that Resveratrol intravitreal helps preserve retinal ganglion cells and suppress TNF-α expression after ischemia-reperfusion injury in the animal model.